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Trastuzumab is an effective therapeutic treatment for Her2-like breast cancer; despite
this most of these tumors develop resistance to therapy due to specific gene mutations
or alterations in gene expression. Understanding the mechanisms of resistance to
Trastuzumab could be a useful tool in order to identify combinations of drugs that elude
resistance and allow a better response for the treated patients. Twelve primary biopsies
of Her2+/hormone receptor negative (ER-/PgR-) breast cancer patients were selected
based on the specific response to neoadjuvant therapy with Trastuzumab and their whole
exome was sequenced leading to the identification of 18 informative gene mutations that
discriminate patients selectively based on response to treatment. Among these genes,
we focused on the study of the ANKRD44 gene to understand its role in the mechanism
of resistance to Trastuzumab. The ANKRD44 gene was silenced in Her2-like breast
cancer cell line (BT474), obtaining a partially Trastuzumab-resistant breast cancer cell
line that constitutively activates the NF-kb protein via the TAK1/AKT pathway. Following
this activation an increase in the level of glycolysis in resistant cells is promoted, also
confirmed by the up-regulation of the LDHB protein and by an increased TROP2 protein
expression, found generally associated with aggressive tumors. These results allow us
to consider the ANKRD44 gene as a potential gene involved in Trastuzumab resistance.
Keywords: Her2+ breast cancer, Trastuzumab resistance, ANKRD44, next generation sequencing, LC-MS/MS,
gene silencing
INTRODUCTION
Her2 is a transmembrane receptor with tyrosine kinase activity. This protein belongs to the EGFR
family which is composed of four receptors: Her1/EGFR, Her2, Her3, and Her4. EGFR proteins
are involved in many biological processes, such as proliferation, differentiation, cell motility and
apoptosis (1), through different signal transduction pathways (2, 3) including the PI3K/Akt and the
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Ras/Raf/MEK/MAPK pathway (4). In physiological condition a
specific level of Her2 is required for breast development (5), but
its amplification and overexpression causes the dysregulation of
normal cellular control and the formation of aggressive breast
tumor cells (1, 6). Genetic alterations in Her2 gene are found
in almost the 30% of breast cancer (BC) patients and are
associated with a poor prognosis (7), causing an increased protein
expression on the tumor cell surface which leads to an increased
cell proliferation, cell survival (8) and tumoral resistance to
anticancer therapies.
The monoclonal antibody Trastuzumab (TRA) is currently
the backbone of treatment both in the adjuvant and in
the advanced setting for patients with Her2-like BC. The
mechanisms, by which TRA inhibits Her2-overexpressing
cancer cells growth, are not completely defined, but down-
modulation of PI3K/Akt and/or Ras/MAPK signaling pathways
are essential features of TRA response leading to eventual
cell cycle arrest (9). However, nearly 25% of patients present
disease progression at 10 years after TRA treatment, in
the adjuvant setting (10) and only 11–15% show a partial
remission when TRA has been administrated as monotherapy
(11, 12). These results indicate that most of the patients
become resistant to TRA, although their initial response.
Several mechanisms of intrinsic and acquired resistance
have been proposed, including disruption of receptor-
antibody interaction (13, 14), compensatory signaling by
other Her family receptors (15), loss of PTEN and mutation
of PIK3A (16, 17), signaling by the insulin-like growth factor I
receptor (18, 19).
In recent years, other potential mechanisms of acquired
resistance to TRA in Her2-like BC have been discovered and
studied, such as the increased phosphorylation of the nuclear
factor kappa B (NF-kB) p65 subunit (20, 21). Understanding the
molecular mechanisms that contribute to the acquired resistance
will ultimately allow for the identification of biomarkers
that can be used to predict response to TRA therapy,
as well as the identification of molecular targets for new
therapeutics development.
In this study, we performed a whole-exome analysis of 12
formalin-fixed, paraffin-embedded (FFPE) biopsies of Her2-like
BC patients composed of Full Responders (FR) and Partial
Responders (PR) to TRA neoadjuvant therapy. We identified a
list of 18 genes whose mutational profile discriminates selectively
the two groups of patients. Among these genes we focused
our attention on the ANKRD44 gene, highly mutated in PR
patients and in particular on a single nucleotide polymorphism
(SNP) found in the PR patients. ANKRD44 gene encodes
for an ankyrin repeat domain protein, member of a putative
regulatory ARS subunit of the protein phosphatase 6 (PP6)
complex (22, 23).
It is well-known that the ARS subunit plays a central role in the
PP6 activity by recognizing phosphoprotein substrate (24). The
ANKRD44 SNP identified by our analysis has an high probability
to be deleterious for the protein conformation. Therefore, we
performed ANKRD44 gene expression silencing in human Her2-
like BC cell line (BT474) to investigate its involvement in
TRA resistance.
Our novel findings have important implications for the




A total of 12 patients with stage III Her2-positive/hormone
receptor-negative (ER-/PgR-) BC were treated with epirubicin
(90 mg/sqm) plus cyclophosphamide (600 mg/sqm) every 3
weeks for 4 cycles followed by paclitaxel (80 mg/sqm, weekly
for 12 weeks) and TRA (loading dose of 8 mg/kg, then at
6 mg/kg every 3 weeks for 18 cycles started in combination
with paclitaxel). Definitive surgical intervention was carried
out within 4 weeks of the final dose of paclitaxel. As
mentioned above, the patients were classified on the basis of
the response to treatment: 6 FR patients and 6 PR patients
(Table 1). The FR patients presented a pathological complete
response (pCR) to the therapy with a definitive dissolvence
of the infiltrating tumor both in the breast and in the
axilla (i.e., ypT0/is ypN0). The PR patients manifested an
incomplete pCR with a neoplastic residue >10% after the
treatment. We collected FFPE tumor biopsies for FR patients
and for PR patients upon surgical removal after pathologist’s
review (Department of Pathology, University of Pisa, Italy)
prior to chemotherapy. Patients who did not completely
respond to the therapy, went into surgery subsequently and
the FFPE primary tumors, post therapy were collected for
the analysis.
Sample Extraction and Preparation
All the samples were checked with H&E by a senior pathologist
who confirmed the low presence of stromal cells in favor of tumor
cells, surely over the 90%.
Genomic DNA was extracted from four 5µm sections of
FFPE primary tumor or from ten 5µm sections of FFPE
tumor biopsies of each sample using the Maxwell R© 16 FFPE
Tissue LEV DNA Purification Kit (Promega, Madison, WI).
DNA samples were then amplified using GenomePlex R© Single




Whole-exome library preparation was performed using Ion
TargetSeqTM Exome Enrichment Kit (Thermo Fisher, Whaltam,
MA) and the Nextera Rapid Capture Expanded Exome Kit
(Illumina, San Diego, California, U.S.) following manufacturer
procedure. Exome analysis was performed using both Ion
ProtonTM Sequencer (Ion Torrent) and NextSeqTM 500 (Illumina,
San Diego, California, U.S.).
Bioinformatic Analysis
Data were automatically analyzed by using the Ion Torrent
server, previously set for the alignment to the human genome
(hg19 version). Raw data generated from Illumina NextSeq500TM
were converted using Bcl2Fastq tools provided by Illumina.
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TABLE 1 | Clinical samples: clinical and pathological informations for the 12 patients under study (6 full responders and 6 partial responders).
Sample Age Biopsy cTNM Stage ER PgR HER-2
(IHC)
Surgery Histology yTNM Response
FR1 66 Ductal infiltrating
carcinoma



























FR4 71 Ductal infiltrating
carcinoma
















FR6 77 Ductal infiltrating
carcinoma







PR1 43 Ductal infiltrating
carcinoma






PR2 44 Ductal infiltrating
carcinoma







PR3 58 Ductal infiltrating
and in situ
carcinoma











































The primary Illumina data analysis of exomes was performed
by using the SeqMule pipeline (25). VCF files obtained from
exome analysis were filtered using Enlis Genome Research.
We started using the following filter: quality score ≥10,
read depth ≥30, allele frequency (as 1000 Genome Project
and Exome Aggregation Consortium) <1% and protein
impact involving missense, non-sense, frameshift and splice
disrupt mutations. For missense mutations we used the Dann
Model (26) to select the predicted deleterious alterations. A
this point we have further refined the research by filtering
the sample using specific database as COSMIC Database,
HerceptinR: Herceptin Resistance Database (http://crdd.
osdd.net/raghava/herceptinr/index.html) and a custom list
of predicted driver genes obtained from CRAVAT (http://
www.cravat.us/CRAVAT/), a web tool dedicated to discover
driver mutations.
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TABLE 2 | Whole exome analysis: list of the 18 informative gene mutations and
corresponding aminoacid changes.
Gene Description rs ID A.A. change
OR6C74 Olfactory receptor family 6
subfamily C member 74
rs4522268 R-62-X-
CEP350 Centrosomal protein 350 rs12124336 S-1517-A
ANKRD44 Ankyrin repeat domain 44 rs35338671 I-94-M
RPTN Repetin rs75957773 E-707-G
FAM161A Family with sequence
similarity 161 member A
rs17513722 I-236-V
















LCT Lactase – R-509-H
PIK3C2G Phosphatidylinositol-4-
phosphate 3-kinase
catalytic subunit type 2
gamma
rs12312266 P-977-L
NCBP1 Nuclear cap binding
protein subunit 1
– R-401-C
OR10J5 Olfactory receptor family
10 subfamily J member 5
– P-182-L
FAT1 FAT atypical cadherin 1 rs751999701 R-2569-H






Empty cells (–) are mutations not yet discovered.
Discriminant Analysis
A discriminant analysis was performed to predict the
TRA resistance by mutational state. As independent
variables, we considered the presence/absence of
mutations in our list of 18 genes. The analysis was
executed by using Tanagra software (https://eric.univ-
lyon2.fr/ricco/tanagra/en/tanagra.html). A cluster analysis
was also performed with the same genes by using Stata 12
(StataCorp LP).
Cell Culture
Human breast cancer cell lines BT474 (ATCC R© HTB-
20TM) deriving from a human breast ductal invasive
carcinoma, were grown in DMEM with 10% fetal bovine
serum (FBS), 100 U/mL penicillin/streptomycin, 0.01 g/L
Insulin and 2 g/L HEPES. Cell lines were incubated at
37◦C in a humidified atmosphere incubator containing
5% CO2.
ANKRD44-shRNA Plasmid Silencing
SureSilencing shRNA Plasmid (Qiagen, Hilden, GE) was used
for silencing the ANKRD44 gene. 8 × 104 of BT474 cells were
seeded in a 6-well plate and transfected in triplicate with Negative
Control shRNA plasmid (shCTRL cells) and shRNA-ANKRD44
plasmid (shANK cells) following manufacturer procedure. Cells
were then positively selected with 800µg/ml of Geneticin, G418
(Sigma-Aldrich), and subsequently kept at a 350µg/ml dose to
maintain the gene silencing selection.
Real Time PCR
Total RNA was extracted using the Maxwell R© 16 LEV
simplyRNA Cells Kit (Promega). Total RNA was then reverse
transcribed to total cDNA using the nanoScript 2 Reverse
Transcription kit (PrimerDesign Ltd., Eastleigh, UK) according
to the manufacturer instructions. Real-time PCR was performed
on cDNAs to detect relative expression of ANKRD44 and
GAPDH for a loading control.
Western Blot Analysis
For total protein extraction, cells were lysed in RIPA lysis
buffer (SDS, Sigma-Aldrich), containing protease/phosphatase
inhibitor cocktail (Cell Signaling Technology, Danvers, MA)
following manufacturer procedure. 10–20 µg of proteins were
separated on a 10% Mini-PROTEAN R© TGX Stain-FreeTM
Precast Gels (Bio-Rad Laboratories) and electro transferred
to nitrocellulose membranes (Trans-Blot R© TurboTM Mini
Nitrocellulose, Bio-Rad Laboratories). Membranes were
then blocked with 5% BSA (Sigma-Aldrich) in PBS-Tween-
20 (PBS-T) buffer and incubated overnight at 4◦C with
the following primary antibodies 1:350 rabbit polyclonal
anti-ANKRD44 (Sigma-Aldrich), 1:1,000 rabbit polyclonal anti-
Akt (Cell Signaling Technology), 1:1,000 rabbit polyclonal
anti-phospho-Akt (Cell Signaling Technology), 1:200
rabbit polyclonal phospho-TAK1 antibody (Biorbyt Ltd.,
Cambridge, UK) and 1:1,000 rabbit polyclonal anti-beta
Tubulin Antibody (Santa-Cruz Biotechnology, Santa Cruz,
CA) used as loading control. Membranes were washed
and incubated with the appropriate secondary antibody
(Abcam, Cambridge, UK) for 1 h at room temperature. Blots
were washed and hybridization signals were measured with
ChemiDoc XRS System (Bio-Rad Laboratories). Images
were analyzed quantitatively using ImageLabTM 4.1 Software
(Bio-Rad Laboratories).
Determination of p65-NF-κB Activity
by ELISA
Proteins were extracted using Nuclear Extraction Kit (Abcam)
according to manufacturer procedure and concentrations
were determined by Bradford reagent (Sigma-Aldrich).
NF-kβ p65 Transcription Factor Assay Kit (Abcam) was
used for measure the p65-RELA transcription factor DNA
binding activity. A known concentration of nuclear and
cytoplasmic proteins were loaded into a 96-well containing
a double stranded DNA (dsDNA) sequence highly specific
for the NF-kβ response element immobilized onto the
bottom of wells according to manufacturer procedure. The
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FIGURE 1 | Whole exome analysis. (A) The dendrogram derived from cluster analysis classified 12 Her2 breast cancer patients based on the mutational profile of 18
informative genes. (B) Histogram representing the ANKRD44 gene relative mutational frequency between full (FR) and partial (PR) responder patients. There is a 2-fold
higher mutation frequency in the PR than in the FR samples. Values are normalized on the total amount of mutations found per group (FR and PR).
activity of NF-kβ (p65) was then detected by measuring
absorbance values at 450 nm with an Infinite R© 200 PRO
NanoQuant plate reader (Tecan, Mannedorf, Switzerland).
Values were then normalized on the respective amount of
loaded protein.
Cell Viability Assay-WST1
shCTRL and shANK cells (7 × 104) were seeded in octuplicate
into a 96-well plate, and allowed to adhere overnight in
a humidified atmosphere of 5% CO2. Cells were treated
with and without 21µg/mL of Trastuzumab (Herceptin R©
150mg, Roche, Basel, SW) at 37◦C for 48 h, incubated
with WST-1 reagent (Clontech Laboratories, Mountain
View, CA) for 1 h at 37◦C and read at 450 nm with the
Infinite R© 200 PRO NanoQuant plate reader (Tecan) to assess
viability. Values were then normalized on the respective
untreated cells.
Soft Agar Colony-Forming Assay
A 6-well plate was prepared with a base layer of 0.6%
low melting point agarose, then 1 × 104 of shCTRL and
shANK cells were mixed with growth medium containing
0.4% agarose and then plated in triplicate onto each well
and allow to solidify. Fresh media with and without TRA
(21µg/mL) was added on top and replaced every 72 h. Plates
were incubated for 1 month in a humidified incubator and
colonies were than fixed with 4% Paraformaldehyde and
stained with 0.005% Crystal Violet (Sigma-Aldrich). Colonies
bigger than 100µm were counted manually in five randomly
selected fields.
Cell Cycle Analysis
Cells were seeded into a 6-well plate. After attachment to plastic
surface, cells were treated with and without TRA (21µg/mL)
for 48 h then trypsinized and fixed for 30min at 4◦C with
70% ice cold Ethanol. 2 × 105 cells were collected in a FACS
tube, washed twice with PBS, and suspended in a 50µg/mL
Propidium Iodide (Sigma-Aldrich) and 20µg/ml RNase (Sigma-
Aldrich) solution. After 30min of incubation at R.T. in the
dark, cells were then scanned for fluorescence intensity in FL3
channel and analyzed with CyFlow R© Cube 8 flow cytometer
(Sysmex-Partec, Görlitz, GE). Analysis of flow cytometry data
was carried out with FCS-Express 4 software (De Novo Software,
Los Angeles, CA).
Cytologic Analysis
To observe the morphology of both shANK and shCTRL
cells, we spread a drop from each cell suspensions over
the glass-slide. Then the slides were allowed to air dry
for 30min and fixed for 10min with 4% formaldehyde.
At the end the slides were stained with Papanicolaou stain
and reviewed by a senior cytopathologist under the inverted
microscope Carl Zeiss Axio Observer Z1FLMot (Carl Zeiss
Microscopy GmbH, Oberkochen, GE) who evaluated the
main characteristics of malignancy in shANK cells: nuclear
pleomorphism, ratio, multinucleation, pleomorphism of nucleoli
and presence of multiple nucleoli. Images were taken with
Carl Zeiss AxioCam Icc1 camera (Carl Zeiss Microscopy
GmbH). These data were then confirmed through flow
cytometric analysis, where multinucleated cells were detected
with a propidium iodide staining. Analysis of flow cytometry




shCTRL and shANK cells were both treated and untreated with
TRA (21µg/mL) for 48 h. The LC-MS/MS experiments were
performed as described previously (27). Briefly, 2 µg of proteins
for each sample were digested with the SP3 digestion protocol
(28) and the resulting peptides labeled with Tandem Mass Tag
10-plex (Thermo Fisher, Waltham, MA, USA). Labeled peptides
were loaded on to RPS cartridges for high-pH fractionation with
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FIGURE 2 | ANKRD44 silencing confers partial trastuzumab resistance and a more aggressive phenotype: (A) ANKRD44 mRNA expression detected by quantitative
real-time RT-PCR analysis in BT474 cells with control empty vector (shCTRL) and with ANKRD44 short interfering RNA (shANK). (A) Gene expression values were
(Continued)
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FIGURE 2 | normalized on housekeeping GAPDH mRNA. (B) Western Blot of proteins extracted from shANK and shCTRL cells. β-Tubulin was used as reference. The
band intensity of ANKRD44 was normalized against the respective β-tubulin, and the ratios shown are against the shCTRL. Data were obtained with ImageLabTM 4.1
Software (Bio-Rad). (C) Viable cell count assessed by WST1 assay. Values were normalized on untreated cells. (D) Colony formation assay histogram. shANK cells
present a 10% increase in the colony formation number respect to the shCTRL cells. Colonies larger than 100µm in diameter were counted from five randomly
selected fields. (E) Cell cycle distribution of shCTRL and shANK cells performed with propidium iodide staining in both untreated (–) and treated (+). Bars present the
percent of cells in G1/G0-phase (black), in S phase (dark gray) and in G2/M phase (gray). (F) Two examples of plurinucleated cells with anisonucleosis obtained by
cytochemistry analysis in shANK cells (Papanicolaou stain × 200). Scale bars: 25µm. (G) Plurinucleate cells distribution of shANK (right) and shCTRL (left) cells fixed
and labeled with propidium iodide in a FL3/SSC dot plot. Quadrant gate regions identify cells with higher scatter intensity (high SSC) and higher concentration of PI,
index of cells with big dimensions, more intracellular complexity and nuclei dysmetria. Percentage of gated cells has been reported in a histogram and shANK cells
present a significant (p < 0.01) increase of multinucleated cells respect to shCTRL cells. Each experiment was repeated in triplicate (D,E) and octuplicate (C) and
each bar represents the mean ± SD of 3 independent experiments. Statistical significance was examined using Student t-test. (*p < 0.05; **p < 0.01; ***p < 0.001).
FIGURE 3 | ANKRD44 silencing increases NF-kβ (p65) activity through TAK1/Akt-pathway. BT474 cells with empty vector (shCTRL) and with ANKRD44 shRNA
(shANK). Cells were treated (+) and untreated (–) with trastuzumab 21µg/ml for 48 h. (A) ANKRD44, Akt and p-Akt-Ser473 western blots. (B) Western blot of p-TAK1
(Thr 184/187). Proteins band intensity was normalized against the respective β-tubulin using ImageLabTM 4.1 Software (Bio-Rad) and normalized on untreated
shCTRL cells. (C) NF-kβ (p65) activity of shANK cells and shCTRL cells. Values represent absorbance measurement (450 nm) with an Infinite 200 PRO NanoQuant
plate reader (Tecan). Values were then normalized on the respective amount of loaded protein. Columns, mean of 3 determinations. Statistical significance was
examined using Student t-test. (*p < 0.05).
the AssayMap BRAVO platform (Agilent Technologies, Santa
Clara, CA).
Samples were injected into an EASY-nLC 1000 coupled to
an Orbitrap Fusion (Thermo Fisher) and analyzed with a data-
dependent method with multi-notch synchronous precursor
selection and MS3 scanning for TMT quantification.
Raw data files were analyzed using Proteome Discoverer
2.1 (Thermo Fisher). MS2 spectra were searched using
SequestHT against a Swissprot Homo sapiens database (20,066
sequences) supplemented with a common contaminant
database (246 sequences). Searches were performed using
the TMT reagents (+229.163 Da, lysine and N-termini) and
carbamidomethyl (+57.021 Da, cysteine) as static modifications,
methionine oxidation (+15.995 Da) as dynamic modification,
20 ppm precursor mass tolerance, 0.6 Da fragment mass
tolerance, and 20 ppm reporter ions tolerance. The search was
performed using fully tryptic peptides with a minimum
length of 6 amino acids and up to 2 missed cleavages.
Results were filtered for a 1% false discovery rate (FDR)
using the Percolator algorithm and additionally filtered for a
minimum Xcorr of 1.8. Statistical analysis was performed with
Perseus software.
Droplet Digital PCR (ddPCR)
shCTRL and shANK cells were both treated and untreated
with TRA (21µg/ml) for 48 h. Total RNA was extracted
and reverse transcribed as described above. ddPCR was
performed on QX100TM ddPCR (Bio-Rad Laboratories) to
detect relative expression of LDHB and TACSTD2 using
GAPDH as loading control. Fluorescence signal quantification
was performed by the droplet reader and the QuantaSoftTM
software (Bio-Rad Laboratories). The ratio of positive
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FIGURE 4 | ANKRD44 silencing confers a different proteomic pattern in shANK cells respect to the control. Volcano plot showing the protein expression comparison
between shCTRL and shANK cells before (A) and after (B) treatment with Trastuzumab. Gray dots represent protein not differently expressed (double sided t-test with
FDR < 0.05). Green and red dots represent proteins significantly up-regulated and down-regulated in the shANK cells, respectively. (C) Log2 of the ERBB2 expression
levels for the shCTRL and shANK before (–) and after (+) treatment with Trastuzumab. (D,E) LDHB and TACSTD2 mRNA expression detected by droplet digital PCR
(ddPCR) analysis in BT474 cells with control empty vector (shCTRL) and with ANKRD44 short interfering RNA (shANK) both treated and untreated for 48 h with
Trastuzumab 21µg/ml. Gene expression values were normalized on housekeeping GAPDH mRNA and the values reported (copies per ml) represent the mean of the
triplicate per sample. Bars: SD. Statistical significance was examined using Student t-test. (*p < 0.05; **p < 0.01).
vs. negative droplets was used to determine the number
of mRNA copies per ml of the target molecule in the
input reaction. Triplicate ddPCR analyses were performed
per sample.
Seahorse XFp Cell Energy Phenotype Test
Metabolic analyses were performed in the Agilent Seahorse
XFp Analyzer (Agilent Technologies). This instrument creates
a transient micro-chamber of only a few microliters in
specialized cell culture microplates which enables the oxygen
consumption rate (OCR), and the extracellular acidification
rate (ECAR), to be monitored in real time. shCTRL and
shANK cells were seeded into a 6-well plate and incubated
overnight in a humidified CO2 incubator. Medium was then
removed and replaced by fresh culture media with and
without TRA (21µg/mL). After 48 h of drug treatment, cells
were plated in 8-well plates for 24 h (2 × 105 cells per
well) in complete media. Cells were changed to unbuffered
DMEM (DMEM supplemented either 25mM glucose, 1mM
sodium pyruvate, 31mM NaCl, 2mM GlutaMax, pH 7.4)
and incubated at 37◦C in a non-CO2 incubator for 60min.
Three measurements were taken before and after sequential
injection of mitochondrial inhibitors (1.0µM oligomycin and
1.0µM FCCP). OCR and ECAR were automatically calculated
by Seahorse XFp software. Every point represents an average
of n= 3.
ROS Production Assay
Reactive oxygen species (ROS) production was quantitated
using CellROX R© Oxidative Stress Reagents (Thermo Fisher) a
fluorogenic probe, according to the manufacturer instructions.
7 × 104 shCTRL and shANK cells were seeded in octuplicate
into a 96-well plate, and the plate was incubated for 24 h.
Cells were incubated for another 48 h with and without TRA
(21µg/mL), then 100 µL of normal media and CellROX
reagent (2.5mM) were added in each well and plates were
incubated for 1 h at 37◦C. Green fluorescence values at 520 nm
were measured with the Infinite R© 200 PRO NanoQuant plate
reader (Tecan). Values were then normalized on the respective
untreated cells.
Statistical Analysis
Experiments were repeated independently a minimum of three
times and values were expressed as means–standard deviation
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TABLE 3 | Proteome analysis: List of proteins with statistically significant
differences in protein expression between shCTRL and shANK cells before and










O00339 MATN2 1.7 2.7
P29508 SERPINB3 1.7 1.9
P06753 TPM3 1.5 3.1
Q14956 GPNMB 1.3 5.5
P22455 FGFR4 1.2 3.0
Q5KU26 COLEC12 1.2 4.6
Q9UGT4 SUSD2 1.2 2.6
P31431 SDC4 1.2 3.1
Q9C0H2 TTYH3 1.1 3.8
P21741 MDK 1.1 5.7
P00533 EGFR 1.1 3.0
O00592 PODXL 1.1 4.4
P20061 TCN1 1.0 7.4
P20810 CAST −0.8 4.8
P09758 TACSTD2 −1.1 6.4
Q8NBJ4 GOLM1 −1.1 3.8
P40199 CEACAM6 −1.2 1.9
P00918 CA2 −1.3 3.9
P07195 LDHB −1.3 3.8
A1L170 C1orf226 −1.5 2.2
shCTRL(+) vs. shANK(+)
Q9UGT4 SUSD2 2.4 3.3
Q9BXS4 TMEM59 1.4 2.0
Q02338 BDH1 1.3 4.2
Q9NR99 MXRA5 1.1 3.8
P21741 MDK 1.1 5.0
P10909 CLU 1.1 3.7
P06753 TPM3 1.1 3.5
O00592 PODXL 1.1 3.2
Q9C0H2 TTYH3 1.0 3.6
P20061 TCN1 0.9 7.0
Q5KU26 COLEC12 0.9 4.4
P53999 SUB1 −0.9 6.3
P20810 CAST −1.0 6.2
P07195 LDHB −1.2 4.8
Q9Y365 STARD10 −1.2 2.4
Q9UKY7 CDV3 −1.2 4.1
P25098 ADRBK1 −1.2 1.6
P35241 RDX −1.3 2.9
P09758 TACSTD2 −1.4 3.0
Uniprot accession number, gene name, fold change and FDR adjusted p-value are
reported for each protein.




We performed whole exome analysis of 12 Her2-like BC
patients treated with a TRA neoadjuvant based therapy. They
were classified on the basis of the response to treatment,
in 6 FR and 6 PR patients. Through NGS analysis, we
identified a total of 18 informative gene mutations present in
the FR or PR patients: OR6C74, CEP350, ANKRD44, RPTN,
FAM161A, FAM175A, MAPK1, FOLH1, GMPR, TGM1, ITPR1,
LCT, PIK3C2G, NCBP1, OR10J5, FAT1, MUC16, and LRG1
(Table 2). We performed discriminant analysis to determine
whether the presence of mutations in the 18 genes discriminate
between FR and PR patients. This is remarked graphically also
by the dendrogram (Figure 1A) performed after hierarchical
clustering analysis.
Interestingly, 50% of PR patients (3 of 6) presents a
particular ANKRD44 SNP (Table 2—rs35338671) predicted to
be deleterious which leads to a I94M amino acid exchange. In
order to evaluate the effect of this variant on ANKRD44 protein,
we perform an in silico test by using MutationTaster software
(http://www.mutationtaster.org/). As expected, the rs35338671
SNP (Table 2) has an high probability to be deleterious for
protein conformation that leads to loss of the 3rd repeat domain
of the ANKRD44 protein thus interfering with the structure and
stability of the protein itself. Moreover, through an in-depth
mutational profile analysis of the two groups of patients we found
that ANKRD44 gene presents a higher number of deleterious
mutations in the PR patients than in FR patients (Figure 1B).
Furthermore, the expression values of ANKRD44 were evaluated
for most patients, based on their availability. In general, lower
expression was observed in PR patients compared to FR. The data
are shown in Figure S1.
These data underline a potential link between ANKRD44 gene
alteration and TRA resistance.
ANKRD44 Silencing Confers Partial
Trastuzumab Resistance and a More
Aggressive Phenotype
Her2-like BT474 BC cell line were transfected with shRNA-
ANKRD44 plasmid (shANK cells) and shRNA-Control plasmid
(shCTRL cells). The expression levels of ANKRD44 gene in
shANK cells and shCTRL cells were examined using real-time
PCR and Western Blot. As shown in Figures 2A,B, ANKRD44
gene and protein was 2-fold downregulated in shANK cells
respect to the shCTRL cells (p < 0.01).
Cell Viability
To determine whether ANKRD44 is involved in TRA resistance,
we examined the effect of TRA on cell viability in both shCTRL
and shANK cells. After 48 h of TRA treatment we observed a
13% increase in shANK proliferation (p < 0.001) respect to the
shCTRL cells (Figure 2C). WST1 assays showed that shCTRL cell
viability was reduced by 65% after TRA treatment while shANK
cells were less affected by the same treatment (52%).
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FIGURE 5 | ANKRD44 silencing turn shANK (BT474) cells metabolism to a more intense glycolysis. BT474 cells with empty vector (shCTRL) and with ANKRD44
shRNA (shANK). Cells were treated (+) and untreated (–) with trastuzumab 21µg/ml for 48 h. (A) Representative results of the metabolic potential of shCTRL and
shANK cells measured using a Seahorse XF. Data shows OCR and ECAR, reflective of energy production by mitochondrial respiration and glycolysis, respectively,
following sequential additions of oligomycin and FCCP. (B) Reactive oxygen species (ROS) production by shCTRL and shANK cells. Values represent green
fluorescence measurement (520 nm) normalized on respective untreated cells. Each experiment was repeated in triplicate and each bar represents the mean ± SD of
3 independent experiments. Bars: SD. Statistical significance was examined using Student t-test. (*p < 0.05; **p < 0.01; ***p < 0.001).
Colony Assay
A similar observation was also noted in the colony formation
assay, which showed that the transformation potential of shANK
cells is significantly higher than that of the shCTRL cells (p
< 0.05; Figure 2D). These results suggest that the shANK
cells present a more aggressive phenotype respect to the
shCTRL cells.
Cell Cycle Analysis
The analysis of the cell cycle phases by flow cytometry
(Figure 2E) showed that TRA induces an increase of the G1 phase
(14.7%) in the shCTRL and a corresponding decrease (12.6%)
of the proliferative cells in S/G2 phases indicating a block in G1
phase. Interestingly, shANK cells are less affected by the G1 arrest
caused by TRA treatment respect to shCTRL cells. In fact, drug
treatment in shANK cells causes a less accentuated increase in the
G1 phase (7.9%) and a decrease in G2 (5.5%) with respect to the
shCTRL cells (p < 0.01 and p < 0.05, respectively).
Cell Morphology Analysis
By a morphological comparison of both shANK cells and
shCTRL cells after Papanicolaou staining, shANK cells present an
increased number of multinucleated cells with nuclear dysmetria
and anisonucleosis (Figure 2F). These features are typical of
the de-differentiated cells that present a more aggressive cancer
phenotype. Morphological data were also confirmed through
flow cytometric analysis of shANK and shCTRL cells both stained
with propidium iodide (Figure 2G). In fact, shANK cells present
a statistically significant (p < 0.001) increase of multinucleated
cells respect to the shCTRL cells.
ANKRD44 Silencing Increase NF-κβ (p65)
Activity Through TAK1/Akt-Pathway
We investigated whether there was any change in the expression
and phosphorylation level of TAK1 and Akt kinases, which are,
negatively regulated by ANKRD44 in physiological conditions
(22, 23). Western blot analysis confirmed silencing of ANKRD44
(shANK) as shown in the first panel of the Figure 3A.
Moreover, we observed that the total form of Akt decreases
in shANK cells treated with TRA respect to the shCTRL. This
result is in accordance with the significant increase of the
phosphorylated forms of Akt (p-Akt-Ser473) and TAK1 (p-
TAK1 Thr184/187) in shANK cells after treatment compared to
the shCTRL (Figures 3A,B). Thus, the results demonstrate that
silencing of ANKRD44 confers to shANK cells an over-activation
of TAK1/Akt protein after TRA treatment. Furthermore, we
extended our study to examine if this over activation of
TAK1/Akt affects the activity of phosphorylated p65-NF-kβ in
shANK cells. As shown in Figure 3C, ELISA results indicated that
p65-NF-κβ levels were increased when shANK cells were treated
with TRA (p < 0.05) respect to shCTRL cells. Thus, the data
indicate that NF-kβ activation in shANK cells could be initiated
by ANKRD44 silencing through the TAK1/Akt pathway.
ANKRD44 Silencing Confers a Different
Proteomic Pattern in shANK Cells Respect
to the Control
To identify possible changes in the proteome after ANKRD44
silencing, we performed quantitative proteomic profiling of
shCTRL and shANK cells. A statistical analysis was performed
to look for different protein expression profiles. To assess the
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FIGURE 6 | Snapshot of trastuzumab resistance pathway. Model of trastuzumab resistance acquisition in BT474 Her2+ breast cancer cell line due to ANKRD44
silencing. (A) In sensitive BT474 cells (shCTRL) without ANKRD44 silencing, trastuzumab blocks the downstream PI3K/Akt pathway (black dotted arrows) and
prevents cell growth. (B) Thanks to ANKRD44 silencing BT474 cells (shANK) become partially resistant to the treatment due to an up-regulation of TAK1/Akt proteins
which constitutively activate NF-kβ p65 subunit and leads to its nuclear accumulation (blue arrows). The nuclear p65 subunit activates the expression of target
pro-inflammatory genes, survival genes and cell cycle regulators. Moreover, the TAK/Akt pathway activates mTORC1 complex which mediates cell proliferation and
simultaneously increase glycolysis rate through an overexpression of Lactate dehydrogenase Beta protein (LDHB).
significance of the protein expression changes we performed a
two-sided Student’s t-test using a permutation-based FDR cutoff
of 0.05. Proteins were ranked in a volcano plot (Figures 4A,B)
according to their statistical p-value (y-axis) and their fold change
(log2 ratio of the protein abundances). As shown in Figure 4A, 7
proteins were up-regulated and 13 proteins were down-regulated
in the untreated shANK cells compared to the control. In the
treated cells (Figure 4B), 8 proteins were up-regulated and 11
proteins were down-regulated in the shANK cells compared to
the shCTRL cells. The list of statistically significant proteins
is reported in Table 3. Interestingly, the levels of HER-2 in
shCTRL and shANK cells was not significantly different before
and after treatment with TRA (Figure 4C) indicating that the
effects observed are due to the ANKRD44 silencing alone. Among
the different proteins obtained by the analysis, we focused our
attention on LDHB and TACTSD2 found up-regulated in shANK
cells both treated and untreated (Figures 4A,B). Through ddPCR
we confirmed that also the mRNA levels of these two proteins
were up-regulated in shANK cells respect to the shCTRL cells in
both treated and untreated cells (Figures 4D,E).
ANKRD44 Silencing Leads Cells
Metabolism to a More Intense Glycolysis
The LDHB protein up-regulation, obtained from LC-ms/ms
analysis suggests that shANK cells could acquire a more
intense glycolysis. To determine this hypothesis, we performed
a metabolic potential analysis on shCTRL and shANK cells
both treated and untreated with TRA. This analysis allows real-
time measurements of ECAR and OCR, which are indicators of
glycolysis and mitochondrial respiration, respectively. As shown
in Figure 5A, we observed that untreated shANK cells presented
higher glycolysis rate (ECAR) and mitochondrial activity (OCR)
with respect to the shCTRL cells (p< 0.01). After TRA treatment,
the trend is inverted and shCTRL cells have a significant higher
ECAR and OCR compared to shANK cells. Interestingly, it is
reported in literature that TRA treatment is associated with
increased reactive oxygen species (ROS) production during
mitochondrial respiration (29). Since ROS production increases
H+ levels, which can interfere with ECAR probes, we decided to
explore the possibility that the increased ECAR that we detected
in the shCTRL cells could have been a false positive result due to
ROS generation after TRA. Thus, we examined ROS generation
in shCTRL and shANK cells after treatment using a commercial
chemiluminescence assay kit. As shown in Figure 5B, the results
indicate that ROS levels were increased when shCTRL cells were
treated with TRA (p < 0.001) compared to shANK cells. So, the
increase of ECAR in shCTRL cells is due to ROS production
while in ANKRD44 silencing is associated to a real increase of
glycolysis. This metabolic modification is consistent with the
detected up-regulation of the LDHB protein in shANK cells.
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DISCUSSION
Treatment of Her2-like BC patients is hindered by resistance
to Her2-targeted therapies. Thus far, the mechanisms by which
TRA inhibits Her2-positive BC development are still not fully
defined. In the present study, through the comparison of patients
with complete response and partial response to the neoadjuvant
therapy with TRA, we identified 18 informative gene mutations
that discriminate selectively the two groups of patients. Among
the 18 genes, we focused our attention on ANKRD44 gene which
mutation profile result to have a higher number of mutations
in the PR compared to the FR patients. Moreover, the SNP
rs35338671 identified in ANKRD44 gene leads to a loss of the
3rd repeat domain of the protein thus interfering with the
structure and the stability of the protein. Interestingly, this
particular SNP was present in 50% PR patients and absent in
the FR patients. These results underlying not only the possible
correlation between the 18 genes mutations and TRA treatment,
but also an interesting correlation between ANKRD44 disruption
and TRA resistance.
ANKRD44 gene encodes for an ankyrin repeat domain
that, together with ANKRD28 and ANKRD52 proteins, create
a putative regulatory ARS subunit of protein phosphatase 6
(PP6) complex (22, 23), a member of the PPP family of
protein Ser/Thr phosphatases. The ARS subunit is involved
in the recognition of phosphoprotein substrates that are
subsequently dephosphorylated by the catalytic subunit PPP6C
(24). Accumulating evidence shows that dysregulated PP6
activity plays a role in melanoma development (30), endometrial
carcinoma (31) and hepatocellular carcinoma (32) but its role in
BC is still unclear.
To understand if ANKRD44 gene could be involved in
TRA resistance, we silenced this gene into a Her2-like human
BC cell line (BT474). Actually, BT474 cells are Her2/ER/PgR
positive, so they may behave differently than our patients who
are Her2 positive but ER/PgR negative. Although, it must be
considered the fact that TRA treatment is administered in both
cases and for this reason we focused our attention only on
the status of Her2.The expression levels of ANKRD44 gene
and protein in both control (shCTRL) and silenced (shANK)
cells were confirmed using real-time PCR and western blot
analysis. Interestingly, shANK cells not only were less affected
by TRA in the viability and in colony formation but also
resulted to be less affected by the phase G1 arrest in the cell
cycle caused usually by TRA treatment (33, 34) with respect
to shCTRL cells. Furthermore, shANK cells showed particular
nuclear features, typical of de-differentiated cells with a more
aggressive cancer phenotype.
From these results we supposed that ANKRD44 gene could
be involved in TRA resistance due to a miss-functional ARS
subunit which is no longer able to detect phosphoprotein
substrates for the catalytic subunit PPP6c. This impairment in
PP6 activity may cause an increased activation of NF-kβ by
TAK1/Akt pathway. In fact, in normal conditions PP6 blocks IL1
downstream signaling pathway (23, 35) by dephosphorylation
of TAK1 (36). This kinase protein is no longer able to perform
its function that leads to phosphorylation and activation of Akt
(37), which in turn activate p38 and IKKS (38), implicated in the
activation of p65-NF-kβ subunit (39), which enters the nucleus
and allows transcription of genes involved in cell proliferation
and in TRA resistance (20, 40). The activated form of TAK1
(pTAK-Thr184/187) and Akt (pAkt-Ser473) were found up-
regulated in shANK cells after TRA treatment compared to
shCTRL cells. These data confirm not only the strictly correlation
between ANKRD44 silencing and TAK1 activation, but also the
TRA resistance of shANK cells. Indeed, TRA treatment inhibits
the PI3K/Akt pathway by Akt dephosphorylation (41, 42) as
confirmed by shCTRL cells, which show a significantly decrease
of pAkt when treated with TRA.
Since ANKRD44 silencing doesn’t allow the inhibition of
TAK1, the activation of the TAK1/Akt pathway in shANK
cells results in increased NF-kβ activation (43) which does not
occur in sensitive cell lines (shCTRL cells) with lower levels
of pAkt. Indeed, we confirmed that p65-NF-kβ transcription
factor was significantly activated in shANK cells after TRA
treatment respect to the treated shCTRL cells despite Her2
expression was similar in both cell lines. The activation of NF-
kβ induces downstream expression of inflammatory cytokines
and anti-apoptotic proteins which promote cell proliferation
(44). Interestingly, from LC-ms/ms analysis we found an up-
regulation of TACSTD2, in shANK cells before and after
treatment with TRA. Experiments conducted on human BC cell
lines showed that TACSTD2 and NF-kβ have roles as regulators
of gene expression with respect to one another (45). TACSTD2
expression is known to inhibit p27 (46), which can increase cyclin
D/E levels associated with the transition from the G1 to the S
phase and this finding is consistent with our results from the cell
cycle analysis. As confirmation to our data, TACSTD2 is reported
in the literature as associated to the epithelial-mesenchimal
transition and therefore to a more aggressive profile, in BC (47).
As previously said, ANKRD44 silencing confers also a
different proteomic pattern to the shANK cells with respect
to control cells. In fact, we found several proteins that were
up-regulated only in shANK cells before and after treatment,
including LDHB. In addition, we found that RPTOR, GATA3,
RPS6KB1, and RICTOR, which are proteins related to the
mTOR pathway, were expressed only in shANK cells and
not in shCTR cells (RPTOR has been quantified in at least
three shANK replicates and not quantified in at least two
shCTRL replicates). Interestingly, the activation of the mTOR
pathway and the overexpression of LDHB has already been
described in the literature (48) and could be associated with
an impairment of PP6 activity due to ANKRD44 silencing. In
fact, PP6 activity is strictly associated with mTOR signaling
pathway by regulating ZNRF2 and eIF2α factors, regulators of
mTORC1 activity (49, 50). LDHB is extensively described in the
literature for its role in promoting tumorigenesis in colorectal
cancer (51) and also for its involvement in the metastatic profile
(52). Recently Nagamine et al. (53) underlined the connection
between drug sensitivity and LDHB, which is overexpressed in
cetuximab-resistant colorectal cancer cell lines. These data are
consistent with the higher glycolysis rate that we observed in the
shANK cells compared to shCTRL cells by metabolic potential
measurements and it is also in accordance with the association
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found in the literature between a glycolytic phenotype and the
TRA resistance (54, 55).
It is interesting to point out that the shCTRL cells appeared
initially to have an increased glycolysis after treatment, proven to
be due to ROS production. These data are in accordance with the
generally accepted model that TRA-mediated growth inhibition
occurs also through increase in ROS production (29).
Based on all the results, in Figure 6, according to our
results, we recapitulate TRA resistance in BC due to ANKRD44
silencing. In Figure 6A the mechanism of action of TRA in
BT474 cells in normal conditions (shCTRL cells) is shown.
TRA blocks the downstream PI3K/Akt pathway with consequent
cell growth arrest. Instead, ANKRD44 silencing in shANK
cells (Figure 6B) allows a partial acquisition of resistance to
TRA due to the up-regulation of TAK1/Akt proteins which
constitutively activates the NF-kβ p65 subunit and leads to its
nuclear accumulation. NF-kβ p65 subunit in turn activates target
pro-inflammatory genes, survival genes and cell cycle regulators.
Indeed TAK1/Akt pathway activates LDHB with consequent
increase in the glycolysis rate.
CONCLUSIONS
In summary, through the comparison of the mutation profile of
patients with different response to TRA treatment we identified
ANKRD44 gene as a possible gene involved in TRA resistance.
We have shown that ANKRD44 gene silencing in a Her2-like
BC cell line activates NF-kβ through the TAK1/Akt pathway and
thus induces a partially resistance to TRA treatment. Moreover,
ANKRD44 silencing promotes an increased glycolysis rate in
resistant cells confirmed by the up-regulation of LDHB protein.
We showed that, after silencing, there is an increase in TACSTD2
protein expression which might be involved in increasing the
transition from G1 to S phase despite TRA treatment. All of these
results allow us to create a snapshot of the acquisition of TRA
resistance in shANK cells after silencing ANKRD44 gene.
Together these results identify ANKRD44 gene as a novel key
factor for TRA resistance but also as a possible predictive marker
for the response to the neoadjuvant therapy with TRA.Moreover,
it supports NF-kβ inhibition as a strategy for improving cell
sensitivity to TRA.
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